Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Emergent BioSolutions Awarded $19.7mn BARDA Contract | Contract Pharma

What are you searching for?

Sign in
Breaking News

Emergent BioSolutions Awarded $19.7mn BARDA Contract

Will develop and manufacture Ebola monoclonal antibodies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Emergent BioSolutions has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) valued at $19.7 million to develop and manufacture cGMP lots of three Ebola monoclonal antibodies in CHO cell lines at a 2,000 liter scale. This contract is the first BARDA task order for an Ebola countermeasure awarded to Emergent under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. Under the scope of this two-year contract, the company will conduct process development, analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance.

“Emergent is pleased to work with BARDA on this contract, which reflects the government’s commitment to enhancing public-private partnerships and, together, taking steps to achieve a state of readiness against emerging public health threats,” said Adam Havey, executive vice president and president, biodefense division, Emergent BioSolutions.

The monoclonal antibodies will be manufactured at Emergent’s Bayview Campus in Baltimore, MD, which is equipped with disposable manufacturing technology such as single use bioreactors that enable production of viral and non-viral products with a quick turnaround. In 2012, it was designated by the U.S. Department of Health and Human Services as a Center for Innovation in Advanced Development and Manufacturing, which allows the company to contract with the U.S. government through task order requests for requirements such as operational readiness, development and manufacturing of CBRN products, warm base maintenance, surge manufacturing, and workforce development. In this facility, Emergent has successfully manufactured product candidates for the company’s pipeline and for ongoing collaborations, including most recently the MVA-EBOZ Ebola vaccine candidate, which is now being evaluated in a Phase 1 clinical study.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics